Ralinepag vs Treprostinil (Remodulin)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Ralinepag

Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.

Phase 3 in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT03626688 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).

Next expected readout: December 2026 · NCT03683186 (registry estimate)

Reported efficacy

Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)

Result source: NCT03626688

Treprostinil (Remodulin)

Marketed by United Therapeutics

Approved in Pulmonary Arterial Hypertensionsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT06317805 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Ralinepag: 5 of 5 rows · Treprostinil (Remodulin): 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRalinepagTreprostinil (Remodulin)
6MWD - Change
absolute change · m
No placebo or comparator arm
-120 m @ 221wka,b,c,d
NCT02279745 · Phase 2 · registry result, not featured evidence
440.8 ma,b,c,d
NCT03055221 · Phase 4 · registry result, not featured evidence
Dropout rate
44.4%e
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
15%
NCT02279160 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonee
NCT03055221 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
15.6%e
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
—
NCT02279160 · Phase 2 · registry result, not featured evidence
10%e
NCT03055221 · Phase 4 · registry result, not featured evidence
Serious AEs
46.7%e
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
10%
NCT02279160 · Phase 2 · registry result, not featured evidence
87.5%e
NCT03055221 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
e
headache 64.4%
diarrhoea 37.8%
pain in jaw 33.3%
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
headache 77.5% (placebo 28.6%)
nausea 50% (placebo 23.8%)
diarrhoea 47.5% (placebo 14.3%)
NCT02279160 · Phase 2 · registry result, not featured evidence
e
abdominal discomfort 18.8%
catheter site pain 18.8%
cough 18.8%
NCT03055221 · Phase 4 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 4.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ralinepag

PVR Change Dyn S Cm5 -52.2 seconds
absolute change · seconds
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Time to First Clinical Worsening Event 13.04 months
time to event · months
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence · converted to months from 56.5 weeks as posted
6MWD - Change 37 m
absolute change · m
No placebo or comparator arm
End of Study (Time of Discontinuation of Study by Sponsor)
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Output 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Index Change L/Min M2 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Pulmonary Arterial Pressure -2 mmHg
absolute change · mmHg
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
PVR 514.6 vs 512 placebo cm @ 22wk
absolute change · cm
NCT02279160 · Phase 2 · registry result, not featured evidence
6MWD - Change 36.2 vs 29.4 placebo m @ 22wk
absolute change · m
NCT02279160 · Phase 2 · registry result, not featured evidence

Treprostinil (Remodulin)

NYHA Class 2.1 Functional Class
absolute change · Functional Class
No placebo or comparator arm
NCT03055221 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (Remodulin)'s landscape